BioMarck Pharmaceuticals, a startup using technology developed at North Carolina State University, has closed on $4 million in new financing.
The funds will be used for a Phase II clinical trial of a drug that could be a treatment for respiratory diseases. The identity of the investors was not disclosed.
BioMarck had raised $6.5 million in financing through two earlier rounds.
The company has also received financial support from the National Institutes of Health.
BioMarck submitted an investigational new drug to the Food and Drug Administration in December of 2005.
Its technology targets a variety of pulmonary diseases, including chronic obstructive pulmonary disease (COPD). COPD kills more than 120,000 people a year in the United States.
Kenneth Adler, a professor of cell biology at NCSU, made the discoveries that led to the development of BioMarck’s technology.
